Revel Pharmaceuticals Inc. was awarded a $648,030 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The funding supports the development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney disease (DKD). The project aims to engineer enzymes that can efficiently cleave the AGE modification carboxymethyl-lysine (CML) from physiological substrates and characterize their activity on relevant DKD proteins and human tissues. Successful completion of this Phase I Small Business Innovation Research (SBIR) project will yield the first therapeutic enzyme designed to remove and repair AGE damage in vivo. Future plans include conducting in vivo efficacy and IND-enabling studies to support an IND submission.
Generated 1/28/25, 8:39 AM